FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies (2026-04-30)
If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines ​unless they appear on the FDA's ⁠drug shortage ⁠list.